What is Bionaut Labs?
Founded in 2016 and headquartered in Los Angeles, California, Bionaut Labs is at the forefront of developing a novel precision medicine treatment modality. This modality utilizes remote-controlled microscale robots to deliver therapies, including biologics, nucleic acids, and small molecule treatments, directly to targeted areas within the central nervous system. This advanced Bionaut medical modality has the potential to fundamentally alter how the biopharmaceutical industry approaches treatment development, enabling enhanced therapeutic indices for improved efficacy and safety. The company's operations are supported by a world-class team of experts in medicine, engineering, and drug development, with additional R&D sites in Israel and Germany.
How much funding has Bionaut Labs raised?
Bionaut Labs has raised a total of $43.2M across 1 funding round:
Series B
$43.2M
Series B (2022): $43.2M with participation from Deep-Insight, OurCrowd, Khosla Ventures, Sixty Degree Capital, and PSPRS
Key Investors in Bionaut Labs
Khosla Ventures
Khosla Ventures is a venture capital firm founded in 2004 that provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies across various sectors including AI, fintech, health, and robotics.
Sixty Degree Capital
Sixty Degree Capital is a global investment firm specializing in healthcare and technology sectors, focusing on AI, cybersecurity, drug development, and digital health, from pre-seed to growth stages.
OurCrowd
OurCrowd is an Israeli-based investment platform founded in 2013 that enables accredited investors and institutions to invest in startups, early-stage companies, and venture funds.
What's next for Bionaut Labs?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for Bionaut Labs, likely focused on scaling its operations, advancing its Bionaut precision medicine treatment modality through clinical trials, and expanding its market reach. This capital infusion is expected to accelerate the development and commercialization of its innovative robotic delivery system for CNS disorders. The company's strategic positioning, combined with its focus on engineering a superior therapeutic index, suggests a trajectory aimed at transforming patient care and establishing new standards in the treatment of complex neurological conditions. Future growth will likely involve further strategic partnerships and continued innovation in medical robotics and drug delivery.
See full Bionaut Labs company page
